Abstract: The present invention relates to a method of preparing a population of stem cells for autologous implantation to a subject. The cells are activated by irradiating the cells with one or more wavelengths of yellow and red and/or green light. In particular, the cells are irradiated with 575-595 nm (5-20 mW), and 630-635 nm or 660-670 nm (10-100 mW) and/or 510-540 nm (10-60 mW) of monochromatic light for 30-60 mins. Preferably the stem cells are adipose-derived stem cells. Also the invention relates to therapeutic applications of the activated stem cells.

Abstract: Provided is a method of treating type 2 diabetes in a subject, comprising administering a polypeptide comprising thymosin, or an active fragment or variant thereof, preferably comprising or consisting of the peptide LKKTETQ (SEQ ID NO: 1).

Abstract: The present invention relates to a method of preparing a population of stem cells for autologous implantation to a subject. The cells are activated by irradiating the cells with one or more wavelengths of yellow and red and/or green light. In particular, the cells are irradiated with 575-595 nm (5-20 mW), and 630-635 nm or 660-670 nm (10-100 mW) and/or 510-540 nm (10-60 mW) of monochromatic light for 30-60 mins. Preferably the stem cells are adipose-derived stem cells. Also the invention relates to therapeutic applications of the activated stem cells.

Abstract: The invention relates to a method of treating HIV or AIDS comprising administering a composition comprising a polypeptide comprising LKKTETQ (SEQ ID NO: 1) or a variant thereof, or administering a composition comprising a peptidomimetic of a polypeptide comprising amino acid sequence LKKTETQ (SEQ ID NO: 1) or a variant thereof.

Abstract: Provided is a method of treating type 2 diabetes in a subject, comprising administering a polypeptide comprising thymosin, or an active fragment or variant thereof, preferably comprising or consisting of the peptide LKKTETQ (SEQ ID NO: 1).